Tencent-Backed InSilico Medicine Raises HK$2 Billion After Pricing IPO at Max Target

MT Newswires Live2025-12-30

InSilico Medicine (HKG:3696) raised HK$2.03 billion in net proceeds from its initial public offering in Hong Kong after pricing its shares at the intended maximum.

The AI-driven drug discovery and development company issued 94.69 million shares at HK$24.05 apiece, according to a Monday disclosure.

The Hong Kong public offering was 1,427.37 times oversubscribed, but the allocation was kept at 9.47 million shares. The international tranche was 26.27 times subscribed, with 85.2 million shares issued.

Sixteen cornerstone investors, which included Tencent Holdings (HKG:0700), subscribed to 37.2 million shares in the IPO.

InSilico Medicine will start trading on the Hong Kong bourse today, Dec. 30.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment